1 / 7

Frontier Pharma Pancreatic Cancer - Aarkstore.com

A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms of action, which provides a striking contrast to the current, chemotherapy dominated, market. Within the pipeline, there are 185 products that act on a first-in-class molecular target, representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target

Wcarone
Download Presentation

Frontier Pharma Pancreatic Cancer - Aarkstore.com

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Frontier Pharma Pancreatic Cancer - Aarkstore.com Category : Pharmaceuticals and Healthcare For More Information Visit : www.aarkstore.com

  2. SummaryPancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market. A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms of action, which provides a striking contrast to the current, chemotherapy dominated, market. Within the pipeline, there are 185 products that act on a first-in-class molecular target, representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. A drastically different pipeline and market composition implies that the approach to pancreatic cancer treatment is changing and first-in-class innovation is playing a significant role in this.  Scope- Gemcitabine based regimens continue to dominate the market, which has seen few new entrants over the past decade. The continued reliance on generic chemotherapies is one reason why the prognosis has shown little improvement. - What survival benefits do current therapies provide? - What are the current unmet needs that the pipeline needs to address? For More Information Visit : www.aarkstore.com

  3. Table of Content 1 Table of Contents 2 1.1 List of Tables 3 1.2 List of Figures 3 2 Executive Summary 4 2.1 Large and Diverse Pipeline Contrasts the Limited Market 4 2.2 Pancreatic Cancer Shows High Levels of First-in-Class Innovation 4 2.3 High Deal Activity Reflects Dynamic Pipeline 4 3 The Case for Innovation 5 3.1 Growing Opportunities for Biologic Products 6 3.2 Diversification of Molecular Targets 6 3.3 Innovative First-in-Class Product Developments Remain Attractive 6 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7 3.5 Sustained Innovation 7 3.6 GBI Research Report Guidance 8 4 Clinical and Commercial Landscape 9 4.1 Disease Overview 9 4.2 Disease Symptoms 9 4.3 Epidemiology 9 For More Information Visit : www.aarkstore.com

  4. List Of Tables Table 1: Tumor Node Metastasis Classification 13Table 2: Pancreatic Cancer Therapeutics, ECOG Performance Status Scores and Description 15Table 3: Pancreatic Cancer Therapeutics, Common Endpoints in Oncology Clinical Trials and their Description 16 Table 4: Pancreatic Cancer Therapeutics, Efficacy of GemcitabineMonotherapy 16 Table 5: Pancreatic Cancer Therapeutics, Efficacy of GemcitabineMonotherapy 17 Table 6: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine in Combination with Eloxatin20 List Of Figures Figure 1: Innovation Trends in Product Approvals 5 Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Product Post Marketing Approval 7 Figure 3: Genetically Altered Signaling Pathways in Pancreatic Cancer 12 Figure 4: Overview of Marketed Products in Pancreatic Cancer 27 Figure 5: Overview of Pipeline Products 30 • Browse full report Or Sample Request @ • http://www.aarkstore.com/pharmaceuticals-healthcare/127902/frontier-pharma-pancreatic-cancer-identifying-and-commercializing-first-in-class-innovation

  5. Related Reports • Opioids Overview to 2021 - An Assessment of Pain Management and Dependence • Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma • United States Vitamin A Industry 2015 Market Research Report • Europe Vitamin A Industry 2015 Market Research Report • Japan Vitamin A Industry 2015 Market Research Report For More Information Visit : www.aarkstore.com

  6. Follow Us https://www.facebook.com/aarkstoredotcom https://twitter.com/aarkstore https://plus.google.com/+Aarkstoredotcom/posts https://www.linkedin.com/company/aarkstore-enterprise For More Information Visit : www.aarkstore.com

  7. Contact Us Office Address Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Mail us at contact@aarkstore.com 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 For More Information Visit : www.aarkstore.com

More Related